Academic and TAVR - Cardiovascular Update

Predictors of permanent pacemaker requirement in aortic stenosis patients undergoing self-expanding valve transcatheter aortic valve replacement using the cusp overlap technique

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).

Pacemaker

Pacemaker Aortic Stenosis Aortic valve

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

MARCH 15, 2024

“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”

TAVR

TAVR Academic Education Cardiovascular Surgery

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

DAIC

MARCH 12, 2024

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR

TAVR Aortic valve Aortic Stenosis

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Modified percutaneous coronary intervention-derived risk models (PARIS and CREDO-Kyoto integer scoring systems) applied to Japanese transcatheter aortic valve replacement patients

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve

Aortic valve TAVR Aortic Myocardial Infarction

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

MARCH 15, 2024

“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”

TAVR

TAVR Academic Education Cardiovascular Surgery

A NOTIONal truth : Surgical AVR deteriorates faster than TAVI, for some mysterious reasons!

Dr. S. Venkatesan MD

FEBRUARY 9, 2024

Reviewing NOTION study, the Nordic TAVI 10 year follow up has just been released (Ref 1) : Caution : Non-academic content This study reports the long-term outcome in low-risk individuals who required AVR. Now, some academic queries ? No doubt ,the Aortic interventional world is applauding and everyone is joining the party.

Aortic valve

Aortic valve Aortic Academic Physiology

Early TAVR trial : Too early to call

Dr. S. Venkatesan MD

JANUARY 17, 2025

While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Expected to improve with polymer valves) The latest trial to join the litereture is EARLY TAVR in October 2024 Here is a brief, personal comment about the paper for non-academic consumption.

TAVR

TAVR Aortic valve Hospital Academic

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Circulation: Cardiovascular Interventions

MARCH 26, 2025

Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).

Aortic valve

Aortic valve Aortic Stenosis TAVR

Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement

Journal of the American Heart Association

MARCH 21, 2025

The primary efficacy end point is the incidence of bleeding events, defined by the VARC3 (Valve Academic Research Consortium3) criteria, at 1year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year.

Aortic valve

Aortic valve Aortic Myocardial Infarction TAVR

Highlights of ACC 2024

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve.

Angina

Angina Myocardial Infarction Aortic valve Coronary Artery Disease

Cardiovascular Update

Predictors of permanent pacemaker requirement in aortic stenosis patients undergoing self-expanding valve transcatheter aortic valve replacement using the cusp overlap technique

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

Webinars

Modified percutaneous coronary intervention-derived risk models (PARIS and CREDO-Kyoto integer scoring systems) applied to Japanese transcatheter aortic valve replacement patients

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

A NOTIONal truth : Surgical AVR deteriorates faster than TAVI, for some mysterious reasons!

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Early TAVR trial : Too early to call

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement

Highlights of ACC 2024

Stay Connected